Nabil Sifo @NabilSifo: "𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐖𝐞𝐞𝐤𝐥𝐲 𝐔𝐩𝐝𝐚𝐭𝐞: 𝐃𝐨𝐮𝐛𝐥𝐢𝐧𝐠 𝐃𝐨𝐰𝐧..."

Germany

Edited

𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐖𝐞𝐞𝐤𝐥𝐲 𝐔𝐩𝐝𝐚𝐭𝐞: 𝐃𝐨𝐮𝐛𝐥𝐢𝐧𝐠 𝐃𝐨𝐰𝐧 𝐨𝐧 𝐆𝐫𝐨𝐰𝐭𝐡 𝐒𝐭𝐨𝐜𝐤𝐬 Dear Copiers and Followers, Starting with a big congratulation for us all on the new all-time high. The portfolio is now above 𝟓𝟓% 𝐘𝐓𝐃 returns. These great returns in the past two weeks were not expected from September statistics. Yet it seems the mix of good stocks selection and rate cut stimula can change the outcome of September. 𝐖𝐡𝐚𝐭 𝐝𝐫𝐢𝐯𝐞𝐬 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭? The USA Federal Reserve finally decided to cut the interest rate by 25 basis points (0.25%), and the possibility of another rate cut in October has risen to 92%. Bond yield, which can be used as a proxy of investor opinion on economic growth and inflation, shows unexpectedly mixed results. The important notice is that the long-term bond ( 10 and 30 years) show an increase in the yield. That means investors are not quite worried about the economic growth in the US. 𝐅𝐚𝐬𝐬𝐢𝐭: this rate cut did not shack the balance Bond–Equity yet. Holders of long-term bonds are still keeping their holdings. Or in other words, the liquidity flow from bond market to equity market did not start yet. I can expect a stock market rally if the FED does two more cuts this year. But only one more cut could lead to another natural market reaction like this one. What is however certain is that growth stocks (Small–Mid cap) are benefiting from the cheap money now. That is why I decided to circulate fund from $NVDA (NVIDIA Corporation) to growth stocks. 𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐜𝐡𝐚𝐧𝐠𝐞𝐬: 𝐑𝐞𝐝𝐮𝐜𝐞𝐝 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 • Last week I decided to secure profit on $NVDA , closing all our positions on this stock. The stock is still a great investment in my opinion, but I expect acceleration in growth stocks after the rate cuts, that is why I freed the liquidity. 𝐀𝐝𝐝𝐞𝐝 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧𝐬 • $CELH (Celsius Holdings Inc.) : I plan to keep DCA on this stock as this pullback is not related to fundamental weakening, probably rather investors securing profit on the stock. • $LFMD (LifeMD Inc) : We also have an old/new portfolio member which I like to call the mini $HIMS (Hims & Hers Health Inc). At the moment the stock is beaten down to a really cheap level which makes it a more appealing buy (in telehealth) than $HIMS . • $CRMD (CorMedix Inc) Trading on a cheap valuation considering the size of the market it operates in, and the company is on a good way of building a diversified product portfolio. Best regards, Nabil Sifo $SPX500 I am a professional risk modeler and an Associate Member of the Chartered Institute for Securities & Investment (CISI), London. All posts reflect my personal opinions only and do not constitute, nor should they be interpreted as, financial advice or a recommendation to buy or sell any securities. 𝐑𝐢𝐬𝐤 𝐖𝐚𝐫𝐧𝐢𝐧𝐠𝐬: Copy Trading does not amount to investment advice | Your capital is at risk | Past performance is not indicative of future results.